i-SENS아이센스

i-SENS swung to a small operating profit in the first half of 2026 but still reported a net loss, with revenue near ₩326B over the trailing twelve months.

i-SENS is a Korean maker of blood glucose monitoring products and point-of-care testing devices such as electrolyte and gas analyzers. Trailing twelve-month revenue is ₩326B with a 3.2% operating margin, but net income is negative at -₩2.7B and free cash flow is negative at -₩7.3B. The share price is ₩16,160, about 41% below its 52-week high of ₩27,600 and 9.1% lower over one year.

What stands out

• Revenue grew 8.3% in 2025 to ₩315B, but operating income fell from ₩10.9B in 2023 to ₩7.9B in 2025 and the company posted net losses in 2024 and 2025.
• Trailing debt is ₩165B against cash of ₩59B, and liabilities are 64.6% of equity.
• Valuation is about 1.4 times book value, with no meaningful earnings-based P/E because of losses; the dividend yield is 0.6%.
• Filings in 2026 include a preliminary consolidated earnings release, a half-year report and several convertible bond and conversion price adjustment notices.
• Over the last 20 trading days, retail investors were net sellers of about ₩1.0B while foreign and institutional investors were net buyers; foreign ownership eased from 25.7% to 24.7%.

What to watch

• The next full-year and quarterly results, to see whether the operating profit improvement holds and turns into net profit.
• Further convertible bond conversions and conversion price adjustments, which could add new shares to the 29.6 million shares currently listed.
• Cash generation, since free cash flow is negative and borrowings are large relative to cash; the data does not describe a specific debt repayment plan.